Seattle Genetics: Clinical Trials: SGN-75

Information for Patients and Physicians

SGN-75 is a humanized anti-CD70 monoclonal antibody attached to a potent, synthetic drug payload, monomethyl auristatin F (MMAF) utilizing Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. CD70 is expressed on a variety of solid tumors, including renal cell carcinoma, pancreatic, ovarian and lung cancer, as well as multiple myeloma and several types of non-Hodgkin lymphoma.

SGN-75 CLINICAL TRIAL

Phase I trial for renal cell carcinoma and non-Hodgkin lymphoma

Single-agent dose-escalation trial assessing the safety, tolerability, pharmacokinetics and antitumor activity of SGN-75 in patients with relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

See Study Details ›

SGN-75 PATIENT RESOURCES

If you have questions about the SGN-75 clinical trial, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.